A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 16.2% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 287 (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: multiplesubjectspfplacebo controlledand pharmacodynamics
  Phrases that lowered it: healthykgblood pressurethe pharmacokineticsfixed
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 7 (raises risk) · Design
• Sponsor's past trials: 1163 (raises risk) · Sponsor's track record
• Primary purpose: basic science (lowers risk) · Design
• Drug's FAERS reports with a death: 23.2% (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 92.3% (raises risk) · Drug's FDA history
• Disease area, psychiatry: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults NCT03126721 · started 2017 · scored riskier than 5% of active trials completed
• Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects NCT01807377 · started 2013 · scored riskier than 8% of active trials completed
• Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects NCT01757756 · started 2012 · scored riskier than 14% of active trials completed
• THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS NCT03916406 · started 2019 · scored riskier than 2% of active trials completed
• A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865 NCT01951144 · started 2013 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.